Can a simple training improve tough cancer conversations?
NCT ID NCT05940272
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new communication training program called Hematolo-GIST for doctors who treat large B-cell lymphoma. The goal is to help doctors better discuss the diagnosis and plan future care with their patients. About 48 people (doctors and patients) will take part to see if the training is practical and well-received.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hematolo-GIST communication training
- What this could lead to
- If successful, this training could improve how doctors discuss lymphoma diagnosis and advance care planning with patients, leading to better patient understanding and satisfaction.
- What could go wrong
- This is a small, early feasibility study with only 48 participants, so results may not apply to all settings. The training may not change patient outcomes or be practical for all clinics.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center (All protocol activities)
RECRUITINGNew York, New York, 10065, United States
-
NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only)
NOT_YET_RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?